Partner with Us

Explore the intellectual properties supporting our platforms and programs to define a licensing or development partnership opportunities around a selected technology, application or territory.

27+ InnovationsOver 100 foundational U.S./PCT patent grants across 8 distinct patent families
2035–2047IP exclusivity horizons across the issued and newer pending rights
7 Patent familiesAvailable for partnerships with wide coverage in principal markets

THE LICENSING OPPORTUNITY

Defined rights.
Shared development ambition.

Metallomix seeks partners to develop and commercialize select intellectual properties through licensing, platform collaborations, and program partnerships. The starting point is identifying whether you are interested in an intellectual property partnerhsips or a territorial exclusivity expansion, followed by selecting a specific field of use, product opportunity, and territory.

Intellectual property partnerships

Select whether you'd like to partner with us on new foundational research, existing platform expansion, or expanding our present programs.

Foundational expansion

Work with us to create new proprietary intellectual property encompassing the metallome modulating platforms. Our foundational knowledge base may seed numerous opportunities to develop advanced metallodrugs and to evaluate their potential in defined therapeutic applications.

Explore
Modulating the metallome homeostasis
Protected rights
18/914,964
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2044
New matter
In development
Licensing route
License the rights to create derivative intellectual property for your intended applications.
Modulation of inflammation and oxidative stress
Protected rights
18/739,957
Rights offering
Licenseable, not assignable
Territories
United States application; PCT filing route reported.
Protection horizon
2044
New matter
In development
Licensing route
License the rights to use isotopically modified zinc for creating derivative intellectual property for your intended applications.

Existing platform expansion

Our isotope-selective modulation (ISM) platform covers a use of enriched isotopes in pharmaceutical formulations. Licensors are welcomed to build on this foundation by developing new metallodrug molecules and compounds beyond zinc-aspartate.

Explore
Isotope-enriched compositions and amino-acid chelates
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2035-2045
New matter
Under development
Licensing route
License the rights to use enriched isotopes for creating the intellectual property for your intended applications.
Isotope-selective modulation (ISM)
Protected rights
US20260029404A1
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2044
New matter
In development
Licensing route
License the rights to use ISM for creating the isotope-selective modulation therapeutics for your intended applications.
64Zn-based antibacterial and antiviral compositions
Rights offering
All cited patents assignable
Territories
United States/PCT
Protection horizon
2035-2037 (antibacterial); 2041 (antiviral)
New matter
Conceptualized. Subject to development.
Licensing route
License the rights to use 64Zn-based compounds for creating the isotope-selective modulation therapeutics for your intended antibacterial and antiviral applications.
64Zn-based molecules for hematological malignancies
Protected rights
US12734240
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2045
New matter
Conceptualized. Subject to development.
Licensing route
License the rights to develop one or more of 64Zn(indole-3-carbinol); 64Zne(quercetin), 64Zne(apigenin), 64Zne(genistein), 64Zne(kaempferol), and 64Zne(chrysin) for your intended applications.

Program-linked opportunities

Our KLS-1 program offers opportunities to expand its use into a variety of indication-specific programs and combination therapies with other drugs. Our current focus is on developing KLS-1 as an oncology pharmaceutical. Our published preclinical research, existing human safety data, CMC, and clinical supply manufacturing provide numerous opportunities for spinning off indication-specific neurological, hepatic and endocrine applications into clinical phase.

Explore
Obesity and nonalcoholic steatohepatitis (NASH)
Protected rights
US 10799530 and 16/722,249
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2039
New matter
Conceptualized. Subject to development.
Licensing route
License KLS-1 to develop NASH and/or obesity treatment; or license the rights to develop new NASH/obesity treatments using 64Zn.
Type 1 and type 2 diabetes
Protected rights
US 10933091; US 11596650
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2039
New matter
Conceptualized. Subject to development
Licensing route
License KLS-1 to develop treatments for type 1 and/or type 2 diabetes; or license the rights to develop new treatments for these indications using 64Zn.
Parkinson's and Alzheimer's diseases
Protected rights
US 11779597 and US 12036238
Rights offering
Licenseable, not assignable
Territories
United States/PCT
Protection horizon
2039
New matter
Conceptualized - Subject to development
Licensing route
License KLS-1 to develop Alzheimer's and/or Parkinson's treatments; or license the rights to develop new treatments for these indications using 64Zn.

Territories and exclusivity

Our current focus is North America, the United Kingdom, and Europe. We are seeking partners to expand the geographic reach of our intellectual property into new markets through territory-specific licensing, development, and commercialization partnerships. Geographic scope and exclusivity are defined for each partnership.

WHAT WE SEEK

Build the next opportunity together

Our focus is on advancing our current programs.

We welcome partners with a defined application, complementary capabilities and a credible path to development and commercialization.